AXIM® Biotechnologies is moving forward with the development of MedChew Rx® pharmaceutical chewing gum products, which are intended as a treatment of multiple sclerosis (MS) symptoms.
The company’s product development partner Quay Pharmaceuticals Ltd. has obtained the necessary licenses from the British government to import the controlled drugs needed for the development of AXIM’s cannabinoid-based pharmaceuticals.
AXIM® and its partners import cannabis strains from the Dutch Government’s Office of Medicinal Cannabis with the specific cannabinoid levels to create products like MedChew Rx®. They then use AXIM®’s patented methods to extract the cannabis oil and purify it into 99 percent pure pharmaceutical-grade cannabinoids.
Using AXIM’s proprietary intellectual properties, they then develop and produce cannabinoid-containing chewing gum products like MedChew Rx®, specially formulated for specific indications.
Once developed, the cannabinoid-based chewing gum products will be placed into clinical trials to prove safety and efficacy, with the end goal of gaining FDA and equivalent international approval as prescription medications.
Formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC), MedChew Rx® is currently being developed as a pharmaceutical drug to treat pain and spasticity associated with MS.
According to the National Multiple Sclerosis Society, “MS is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.”
The causes of MS are still unknown; however, scientists believe the disease is triggered by environmental factors in a person genetically predisposed to respond. Most people with MS are diagnosed between the ages of 20 and 50, but the progress, severity, and specific symptoms of MS in any one person cannot yet be predicted. The average person in the United States has about a one in 750 chance of developing MS in their lifetime.
The value of the MS treatment market is estimated to reach nearly $25 billion by 2024, according to a report by Grand View Research, Inc. This increase is linked to both a development of new, more effective treatment options, as well as an overall increase of MS diagnosis. It is estimated that 2.3 million people are living with multiple sclerosis worldwide.
Now that AXIM® Biotechnologies has obtained their license from the British government to import controlled substances, they are able to move beyond CBD and into creating THC-based medications as well. This gives them the freedom to explore how a range of cannabinoid treatments may be used to as an option for difficult to treat conditions.
Learn more about AXIM® Biotechnologies on our news feed.
